Agnès Rode

Agnès Rode

Auto-generated profile, based on publicly available information

Agnès Rode


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2011 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
CMCapucine Micol
Capucine Micol
JMJulien Marsot
Julien Marsot
NBNawele Boublay
Nawele Boublay
FPFrank Pilleul
Frank Pilleul
YBYves Berthezene
Yves Berthezene
ARAgnès Rode
Agnès Rode

1 November 2015 in European Journal of Radiology
Verified
Journal Article
Closed access
TBThomas Brunel
Thomas Brunel
AGAymeric Guibal
Aymeric Guibal
CBCamille Boularan
Camille Boularan
CDChristian Ducerf
Christian Ducerf
JMJean-Yves Mabrut
Jean-Yves Mabrut
ARAgnès Rode
Agnès Rode


23 August 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKayvan Mohkam
Kayvan Mohkam
MRMichel Rayar
Michel Rayar
JAJean-Philippe Adam
Jean-Philippe Adam
FMFabrice Muscari
Fabrice Muscari
ARAgnès Rode
Agnès Rode
JMJean-Yves Mabrut
Jean-Yves Mabrut
The majority of patients undergoing hepatectomy for hepatocellular carcinoma (HCC) suffer from underlying liver disease and are exposed to the risk of postoperative ascites, which is favored by an imbalance between portal venous inflow and a diminished hepatic volume. Finding a reversible, non-invasive method for modulating the portal inflow would be of interest as it could be used temporarily during the early postoperative course. Somatostatin, a well-known drug already used in several indications, may limit the risk of postoperative ascites and liver failure by decreasing portal pressure after hepatectomy for HCC in patients with underlying liver disease. We aimed to evaluate the impact of somatostatin postoperative infusion on the incidence of ascites following hepatectomy by laparotomy for HCC in patients with underlying liver disease. The SOMAPROTECT study is a multicenter randomized double-blind placebo controlled phase III trial comparing two arms of patients with underlying liver disease undergoing hepatectomy for HCC by open approach. All patients will have primary abdominal drainage before closure. Patients in the experimental arm will receive a postoperative intravenous infusion of somatostatin during 6 days. Patients in the control group will receive a placebo infusion for the same duration. The primary endpoint will be the presence or absence of postoperative ascites occurring during the 90-day postoperative course, defined as ≥500 ml/24 h of fluid in the drains during at least 3 days or any ascites requiring an invasive procedure comprising percutaneous puncture or drainage. Secondary endpoints will be duration and total volume of ascites, postoperative 90-day mortality and morbidity, liver failure, acute renal failure, length of stay in intensive care unit and hospital stay. The total number of patients to be enrolled was calculated to be 152. Postoperative ascites remains a major issue after hepatectomy for HCC as it is associated with increased morbidity, liver and renal failure, the need for specific treatments and prolonged hospital stay. This study represents the first randomized controlled trial to assess the benefits of somatostatin on the risk of postoperative ascites after surgery for HCC. NCT02799212 (ClinicalTrials.gov identifier). Registered prior to conducting the research on 9 June 2016.

1 April 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
AHAudrey Haquin
Audrey Haquin
MSMonica Sigovan
Monica Sigovan
SSSalim Aymeric Si-Mohamed
Salim Aymeric Si-Mohamed
JMJean-Yves Mabrut
Jean-Yves Mabrut
AMAnne-Frédérique Manichon
Anne-Frédérique Manichon
LBLoïc Boussel
Loïc Boussel
Objective:To evaluate the correlation between the gastroduodenal artery (GDA) haemodynamic changes and the degree of coeliac axis (CA) stenosis using phase-contrast MRI.Methods:The study was institutional review board approved, and written informed consent was obtained from patients included prospectively. A two-dimensional phase-contrast MRI was performed in 23 patients scheduled for a potential complex supramesocolic surgery, in a plane perpendicular to the GDA, during inspiration and expiration. The peak and mean velocities (Vp and Vm), mean flow rate (Qm) and flow direction at inspiration and at expiration have been correlated with the degree of CA stenosis evaluated by CT.Results:13 of 23 patients presented CA stenosis due to the median arcuate ligament (34–80% of stenosis), 4 of them had associated atheromatous calcifications. Vp, Vm and Qm of GDA presented a significant and linear relationship with the degree of CA stenosis, at inspiration as well as at expiration (r > 0.74, p < 0.001). Velocities ...

3 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ASAndrea Skanjeti
Andrea Skanjeti
NMNicolas Magand
Nicolas Magand
DDDidier Defez
Didier Defez
JTJeremie Tordo
Jeremie Tordo
ARAgnes Rode
Agnes Rode
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
Selective Internal Radiation Therapy (SIRT) is used for the treatment of hepatic tumors. The aim of this retrospective study was to compare two dosimetric approaches based on 99mTc-MAA SPECT/CT and 90Y PET/CT, using Simplicit90Y™ versus the supplier suggested method of activity calculation. A total of 19 patients underwent 21 SIRT after baseline angiography and 99mTc-MAA SPECT/CT, followed by 90Y PET/CT. Overlap between 99mTc-MAA and 90Y-microspheres was quantified with different thresholds isocontours. The perfused volume and tumor absorbed dose were estimated using Simplicit90Y™ based on SPECT/CT and PET/CT, then compared with the supplier suggested method. These data were related to overall survival to evaluate their prognostic impact. The overlap between PET/CT and SPECT/CT was dependent on thresholds, decreasing with an increasing threshold. The overlap between the 99mTc-MAA and 90Y-microspheres biodistributions versus the tumor distribution on morphological imaging was suboptimal, in particular for small tumor volume. The tumor absorbed dose estimated after 90Y PET/CT was not different from tumor absorbed dose estimated after SPECT/CT. The Perfused lobe absorbed dose was significantly lower while the volume of the perfused lobe was significantly higher when estimated by Simplicit90Y™ compared to the supplier suggested conventional approach. A statistical parameter based on overlap between tumor and 90Y-microspheres distribution as well as tumoral dosimetry was significantly related to the overall survival. Post-treatment imaging remains paramount to estimate the irradiation dosimetry, due to an imperfect overlap. The perfused volume could be estimated from functional imaging, given its impact on dosimetry. Finally, survival seems related to tumoral overlap and dosimetry.